Evidence map›Paper›PMID 32016486›Full record

ArticleHerz2020

[Diagnostics and treatment of chronic heart failure : Update 2020].

Gülmisal Güder, Georg Ertl, Christiane E Angermann

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Herz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gülmisal GüderMedizinische Klinik und Poliklinik I, Kardiologie, Universität Würzburg, Würzburg, Deutschland.
Georg ErtlDeutsches Zentrum für Herzinsuffizienz, Universität und Universitätsklinikum Würzburg, Haus A 15, Am Schwarzenberg 15, 97078, Würzburg, Deutschland.
Christiane E AngermannDeutsches Zentrum für Herzinsuffizienz, Universität und Universitätsklinikum Würzburg, Haus A 15, Am Schwarzenberg 15, 97078, Würzburg, Deutschland. angermann_c@ukw.de.
Universitätsklinikum Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure is a systemic disease. As populations are aging worldwide, the prevalence and importance of comorbidities as major determinants of heart failure symptoms, disease progression and prognosis are increasing. Since the last version of the European Society of Cardiology guidelines for the diagnosis and treatment of heart failure was published in 2016, promising novel pharmacotherapies for chronic heart failure and its comorbidities and new device-based treatment and monitoring options have become available; however, the broad range of therapeutic options as well as the diagnostic and therapeutic implications of comorbidities render the treatment of heart failure increasingly more complex. This review aims to provide practical guidance for a rational up-to-date approach to the evidence-based management of heart failure.

Indexed as

ComorbidityDevice-based therapyDiagnosisPharmacotherapyTelemonitoring

Identifiers

PMID32016486
OpenAlexW3004584042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.